Evolution of Gender-Related Differences in Outcomes From Two Decades of Endovascular Aneurysm Repair (EVAR)  by Chung, Christine et al.
Fig 2. Secondary patency rates by KM analysis were 93.8% at 12 months,
93.8% at 24 months, and 89.3% at 36 months.
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Objectives: Women are under-represented in trials that set guidelines
for aortic aneurysm management. Several studies reported inferior outcomes
in women compared with men after endovascular aneurysm repair (EVAR).
We investigated the relationship between gender and outcomes after EVAR.
Methods: A total of 1380 consecutive patients underwent elective
EVAR from 1992 to 2012. Baseline, intraoperative, and postoperative vari-
ables were analyzed from a prospective database.
Results: The cohort consisted of 214 women (15.5%) and 1166 men
(84.5%). Women were older than men at repair (77.8 vs 74.5 years; P <
.001) and had less cardiac disease (P ¼ .005). They had shorter (19.8 6
12.9 mm vs 26.3 6 14.7 mm; P < .001), more angulated aortic necks
(38.8 6 16.1 vs 31.2 6 14.7; P < .001) and fewer iliac aneurysms (P ¼
.002). Women had more arterial reconstructions (iliac conduits, P ¼ .006;
thrombolysis and thrombectomy,P¼ .013; patch angioplasty, P< .001; end-
arterectomy,P< .001),more perioperative complications (11.2% vs 6.3%;P¼
.009), and in-hospital days (4.1 days vs 3.4 days;P¼ .029). Perioperativemor-
tality was equivalent (women: 2% vsmen: 2.3%;P¼ .73).Mean follow-upwas
30.9 months. Women and men experienced equivalent endoleaks, arterial
reinterventions, aneurysm-related deaths, and overall survival.
Conclusions: Female gender is associated with more periprocedural
complications; however, it does not affect long-term reinterventions or survival.
Further studies are warranted to elucidate the effect of gender on outcomes.
This data should be considered when selecting EVAR for men and women.
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Midterm Results of Stenting of Femoropopliteal Lesions Using
Interwoven Nitinol Stents
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2University of Arkansas, Little Rock, ArkFig 1. Primary patency rates by KM analysis were 85.6% at 12 months,
83.1% at 24 months, and 76.7% at 36 months.Objectives: The Supera stent (Abbott Laboratories, Abbott Park, Ill)
has a unique biomimetic design allowing for axial and longitudinal ﬂexibility
and fracture resistance. The aim of this retrospective study was to assess the
midterm primary patency of Supera stents used to treat patients with super-
ﬁcial femoral and popliteal arterial disease by a single practice.
Methods: From April 2010 to December 2011, 48 patients and 54
limbs with symptomatic femoropopliteal lesions underwent angioplasty
and stenting with the Supera stent. Five patients had no follow-up and
were excluded. Patient demographics, radiographic imaging, lesion mor-
phologies, procedural reports, reinterventions, and follow-up clinical visit
notes were reviewed. Primary patency was deﬁned as clinical resolution of
symptoms and no secondary intervention. The 12-, 24-, and 36-month pri-
mary and secondary patency rates were estimated using Kaplan-Meier
analysis.
Results: A total of 48 consecutive patients (42 males, six females),
54 limbs, mean age 64.3 years (range, 51-87 years) received Supera stents as
part of their treatment for femoropopliteal disease.Primary indications for inter-
vention included claudication, rest pain, and tissue loss at rates of 54% (29 of
54), 26% (14 of 54), and 20% (11 of 54), respectively. Twenty-two percent
of lesions were TransAtlantic Inter-Society Consensus (TASC) A or B, and
78% were C or D. Mean lesion length was 24.0 cm (range, 3-51 cm). Mean
follow-up was 27.5 months (range, 1-45). The ankle-brachial index increased
from 0.58 6 0.20 preoperatively to 0.77 6 0.18 postoperatively (P ¼
.00004). Primary, primary assisted, and secondary patency rates at the latest
follow-up were 79.6%, 88.9%, and 92.3%, respectively (Table). Long lesions
>30 cm (33%; 18/54) had primary, primary-assisted, and secondary patency
rates at latest follow-upof 83%, 89%, and 94%, respectively.Cumulative primary
patency rates by Kaplan-Meier analysis at 12, 24, and 36 months was 85.6%,
83.1%, and 76.7%, respectively (Fig 1). Secondary patency rates by Kaplan-
Meier estimates at 12, 24, and 36 months were 93.8%, 93.8%, and 89.3%,
respectively (Fig 2). No stent fractures were found at clinical follow-up.
Conclusions: Our midterm results show that Supera stents are dura-
ble in treating femoropopliteal lesions, with notably high patency rates in
long lesions.
Table. Patency rates as a function of lesion length
1-15 cm 16-30 cm >30 cmPatency
(n ¼ 18),
No. (%)(n ¼ 18),
No. (%)(n ¼ 18),
No. (%)Primary patency 13 (72.2) 15 (83.3) 15 (83.3)
Primary-assisted patency 16 (88.9) 16 (88.9) 16 (88.9)
Secondary patency 17 (94.4) 16 (88.9) 17 (94.4)
